This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A UNIQUE monovalent acellular pertussis vaccine composed only of detoxified pertussis toxin (toxoid) has passed its first efficacy field trial with flying colors. In a study involving nearly 3500 children, the vaccine, which had earlier undergone smaller safety and efficacy studies (JAMA. 1992;268:958-959), was shown to be more than 70% effective and elicited no serious adverse effects.
The trial was randomized, double blind, and placebo controlled. It was conducted in Göteborg, Sweden, under the supervision of Birger Trollfors, MD, and John Taranger, MD, both of whom are professors of pediatrics at the University of Göteborg. Taranger reported the latest findings at the 95th meeting of the American Society for Microbiology, held in Washington, DC. "In the vaccinated children who did acquire pertussis, the disease was less severe and lasted for a shorter period than among nonvaccinated controls," he said.
First Field Trial Results
This study marks the first results in
Marwick C. Acellular Pertussis Vaccine Scores High in Trial. JAMA. 1995;273(24):1892-1893. doi:10.1001/jama.1995.03520480010004